Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of KT110 vs Prazosin + Cyproheptadine in Healthy Volunteers
NCT06147622Phase 1Completed
- Sponsor
- Kinnov Therapeutics
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of KT-110 in alcohol use disorder (AUD) (2 arms), sponsored by Kinnov Therapeutics. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration at Day 4, Area Under the Curve from time 0 to infinity at Day 4 and 4 more. Started Apr 2024; status: completed.
02
Drugs
KT-110
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06147622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147622.